about
The epidemiological impact of antiretroviral use predicted by mathematical models: a review.Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 ProteasePrevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortFluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsProtease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.Transmission networks of drug resistance acquired in primary/early stage HIV infection.Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventionsMechanism of HIV antiretroviral drugs progress toward drug resistance.The physical, emotional and interpersonal impact of HAART: exploring the realities of HIV seropositive individuals on combination therapy.Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.Development of peptide inhibitors of HIV transmission.
P2860
Q24814633-5DF515A6-B729-44EA-90B8-AD583C0C863AQ27675818-E951C5E2-6A22-4CA7-AE34-FF91918E46BCQ28475698-3C708BC7-1C36-4940-BCDD-28031C34418EQ35156768-030509D5-E8CA-4A9E-B629-81458E874A1CQ35579833-6FE712E0-9E27-4565-B6BB-69DBF62D9E58Q35636029-2219CAE8-52F2-4503-871B-647DC5099012Q35962627-EE2CFA06-199D-42BB-A3E5-8510E1CAE881Q37115372-4ED8CFCC-EC67-44A8-B56E-1240C8DB4693Q37206422-0A64EC0D-D2CE-44A8-B414-76FDF9B2F6F2Q37961181-F6202156-CCEF-4122-A2C0-B7CC12EB0D71Q40427185-36780BD0-DBE9-4651-A53C-7E8C43BFEAEEQ46307515-DEF85EFB-9FC5-4B6D-B8DE-7653A9FE0618Q55317261-E779C40B-CA76-43F5-B2DF-7531A11AB8F3
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
HIV-1 drug resistance: can we overcome?
@ast
HIV-1 drug resistance: can we overcome?
@en
HIV-1 drug resistance: can we overcome?
@nl
type
label
HIV-1 drug resistance: can we overcome?
@ast
HIV-1 drug resistance: can we overcome?
@en
HIV-1 drug resistance: can we overcome?
@nl
prefLabel
HIV-1 drug resistance: can we overcome?
@ast
HIV-1 drug resistance: can we overcome?
@en
HIV-1 drug resistance: can we overcome?
@nl
P2093
P2860
P356
P1476
HIV-1 drug resistance: can we overcome?
@en
P2093
Bluma G Brenner
Dan Turner
Mark A Wainberg
P2860
P304
P356
10.1517/14712598.2.7.751
P407
P577
2002-10-01T00:00:00Z